Genetic Signatures logo

GSS - Genetic Signatures Share Price

A$1.19 0.0  0.0%

Last Trade - 4:56am

Small Cap
Market Cap £94.3m
Enterprise Value £74.5m
Revenue £16.2m
Position in Universe 685th / 1911
Unlock GSS Revenue
Relative Strength (%)
1m -25.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -59.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.05 3.35 4.30 5.21 7.18 14.1 33.5 28.8 +47.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, GeneticSignatures Ltd revenues increased from A$3.7M to A$18.8M.Net income totaled A$4.5M vs. loss of A$2.3M. Revenuesreflect Asia Pacific segment increase from A$2.4M toA$15.1M, EMEA segment increase from A$90K to A$3M. NetIncome reflects Other income increase from A$6K to A$85K(income), Travel and accommodation decrease of 34% to A$90K(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


GSS Revenue Unlock GSS Revenue

Net Income

GSS Net Income Unlock GSS Revenue

Normalised EPS

GSS Normalised EPS Unlock GSS Revenue

PE Ratio Range

GSS PE Ratio Range Unlock GSS Revenue

Dividend Yield Range

GSS Dividend Yield Range Unlock GSS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
GSS EPS Forecasts Unlock GSS Revenue
Profile Summary

Genetic Signatures Limited is a molecular diagnostics company. The Company is engaged in the research and commercialization of identifying individual genetic signature to identify diseases and disabilities, and the sale of associated products into diagnostic and research market place. It is focused on the development and commercialization of its platform technology, 3Base. The Company has a suite of polymerase chain reaction (PCR)-based products for the detection of infectious diseases under the EasyScreen brand. Its product portfolio includes EasyScreen detection kits and MethylEasy research kits. The Company's 3base technology forms the basis of its EasyScreen Pathogen Detection Kits. Its EasyScreen products provide hospital and pathology laboratories with the molecular tools to screen for an array of infectious pathogens. Its MethylEasy research kits include Methyl Easy Xceed, which is a bisulfite modification research kit for the detection of methylation patterns in genes.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated February 15, 2001
Public Since March 31, 2015
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index S&P/ASX All Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 142,874,746
Free Float (0.0%)
Eligible for
GSS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GSS
Upcoming Events for GSS
Frequently Asked Questions for Genetic Signatures
What is the Genetic Signatures share price?

As of 4:56am, shares in Genetic Signatures are trading at A$1.19, giving the company a market capitalisation of £94.3m. This share price information is delayed by 15 minutes.

How has the Genetic Signatures share price performed this year?

Shares in Genetic Signatures are currently trading at A$1.19 and the price has moved by -38.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Genetic Signatures price has moved by -53.01% over the past year.

What are the analyst and broker recommendations for Genetic Signatures?

There are no analysts currently covering Genetic Signatures.

When will Genetic Signatures next release its financial results?

Genetic Signatures is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Genetic Signatures dividend yield?

Genetic Signatures does not currently pay a dividend.

Does Genetic Signatures pay a dividend?

Genetic Signatures does not currently pay a dividend.

When does Genetic Signatures next pay dividends?

Genetic Signatures does not currently pay a dividend.

How do I buy Genetic Signatures shares?

To buy shares in Genetic Signatures you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Genetic Signatures?

Shares in Genetic Signatures are currently trading at A$1.19, giving the company a market capitalisation of £94.3m.

Where are Genetic Signatures shares listed? Where are Genetic Signatures shares listed?

Here are the trading details for Genetic Signatures:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: GSS
What kind of share is Genetic Signatures?

Based on an overall assessment of its quality, value and momentum, Genetic Signatures is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Genetic Signatures share price forecast 2021?

Shares in Genetic Signatures are currently priced at A$1.19. At that level they are trading at 0.169% discount to the analyst consensus target price of 0.00.

Analysts covering Genetic Signatures currently have a consensus Earnings Per Share (EPS) forecast of 0.037 for the next financial year.

How can I tell whether the Genetic Signatures share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genetic Signatures. Over the past six months, the relative strength of its shares against the market has been -40.31%. At the current price of A$1.19, shares in Genetic Signatures are trading at -35.7% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Genetic Signatures PE Ratio?

The Genetic Signatures PE ratio based on its reported earnings over the past 12 months is 36.36. The shares are currently trading at A$1.19.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Genetic Signatures?

Genetic Signatures's management team is headed by:

Nickolaos Samaras - NEC
John Robert Melki - CEO
Michael Aicher - EDR
Douglas S Millar - CSO
Susan Keese - GMG
Anthony Radford - DRC
Peter Manley - CFO
Neil Gunn - DRC
Who are the major shareholders of Genetic Signatures?

Here are the top five shareholders of Genetic Signatures based on the size of their shareholding:

Asia Union Investments Pty. Ltd. Corporation
Percentage owned: 26.24% (37.5m shares)
Perennial Value Management Ltd. Investment Advisor
Percentage owned: 14.92% (21.3m shares)
FIL Investment Management (Hong Kong) Limited Investment Advisor
Percentage owned: 7.68% (11.0m shares)
Fidelity Funds - Pacific Fund Mutual Fund
Percentage owned: 6.39% (9.13m shares)
Regal Funds Management Pty. Ltd. Hedge Fund
Percentage owned: 5.97% (8.54m shares)
Similar to GSS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.